Implementation of a Prehospital Stroke Triage System Using Symptom Severity and Teleconsultation in the Stockholm Stroke Triage Study
JAMA Neurol 77:691-699, Mazya, M.V.,et al, 2020
Characteristics and Outcomes in Patients with COVID-19 and Acute Ischemic Stroke
Stroke 51:e254-e258, Ntaios, G.,et al, 2020
Neurologic Outcomes in Pediatric Cardiac Arrest Survivors Enrolled in the THAPCA trials
Neurol 91:e123-e131, Ichord, R.,et al, 2018
Acute Spinal Cord Compression
NEJM 376:1358-1369, Ropper, A.E. & Ropper, A.H., 2017
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
NEJM 372:1009-1018, Campbell, B.C.V.,et al, 2015
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
The Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) Scale
Stroke 43:2871-2876, Pescini, F.,et al, 2012
Cortical Lesions in Primary Progressive Multiple Sclerosis: A 2-Year Longitudinal MR Study
Neurol 72:1330-1336, Calabrese,M.,et al, 2009
Percutaneous Clot Removal Devices in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Arch Neurol 65:1024-1030, Stead,L.G.,et al., 2008
The Alcohol Withdrawal Syndrome
JNNP 79:854-862, McKeon,A.,et al., 2008
Longitudinal Follow-Up of "Benign" Multiple Sclerosis at 20 Years
Neurol 68:496-500,480, Sayao,A-L.,et al, 2007
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Functional Recovery After Rehabilitation for Cerebellar Stroke
Stroke 32:530-534, Kelly,P.J.,et al, 2001
Comparisons of Patient Self-report, Neurologic Examination, and Functional Impairment in MS
Neurol 56:934-937, Hoogervorst,E.L.J.,et al, 2001
Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000
Baseline NIH Stroke Scale Score Strongly Predicts Outcome after Stroke, A Report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST)
Neurol 53:126-131, Adams,Jr.,H.P.,et al, 1999
Benign Multiple Sclerosis? Clinical Course, Long Term Follow Up, and Assessment of Prognostic Factors
JNNP 67:148-152,138, Hawkins,S.A.&McDonnell,G.V., 1999
Quality of Life in Patients and Partners After Aneurysmal Subarachnoid Hemorrhage
Stroke 29:798-804, Hopp,J.W.,et al, 1998
Intracranial Aneurysms
NEJM 336:28-40, Schievink,W.I., 1997
A Prediction Model for Functional Recovery in Stroke
Stroke 28:550-556, Stineman,M.G.,et al, 1997
Paramedian Pontine Infarction
Stroke 28:809-815, Kataoka,S.,et al, 1997
The Impact of Inpatient Rehabilitation on Progressive Multiple Sclerosis
Ann Neurol 42:236-244, Freeman,J.A.,et al, 1997
Ischemic Lesion Volumes in Acute Stroke by Diffusion-Weighted MRI Correlate with Clinical Outcome
Ann Neurol 42:164-170, Lovblad,K-O.,et al, 1997
Acute Stroke:Prognosis & Prediction of Effect of Med Treat Outcome & Health Care Util, Copenhagen Study
Neurol 49:1335-1342, Jorgensen,H.S.,et al, 1997
Prognostic Value of the Hyperdense Middle Cerebral Artery Sign and Stroke Scale Score Before Ultraearly Thrombolytic Therapy
AJNR 17:79-85, Tomsick,T.,et al, 1996
Functional Outcome in Patients with Lacunar Infarction
Stroke 27:842-846, Samuelsson,M.,et al, 1996
'Malignant'Middle Cerebral Artery Territory Infarction
Arch Neurol 53:309-315, Macke,W.,et al, 1996
Treatment of Advanced Parkinson's Disease by Posterior GPi Pallidotomy:1-Year Results of a Pilot Study
Ann Neurol 40:355-366, 3411996., Baron,M.S.,et al, 1996
Comparison of Neurological Scales and Scoring System for Acute Stroke Prognosis
Stroke 27:1817-1820, Muir,K.W.,et al, 1996
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Posttraumatic Headache
Semin Neurol 14:40-45, Packard,R.C., 1994
Measuring Physical Impairment and Disability with the Chedoke-McMaster Stroke Assessment
Stroke 24:58-63, Gowland,C.,et al, 1993
Interferon Beta-1b is Effective in Relapsing-Remitting MS
Clinical Results of a Placebo-Controlled Trial, IFNB MS Study Grp, Neurol 43:655-661, 64193., , 1993
Interferon Beta-1b is Effective in Relapsing Remitting MS, MRI Analysis Results of Placebo-Control Trial
Neurol 43:662-667, 6411993., Paty,D.W.,et al, 1993
Prediction of Non-Survival After Trauma:Innsbruck Coma Scale
Lancet 338:977-978, Benzer,A.,et al, 1991
Predictors of Stroke Outcome Using Objective Measurement Scales
Stroke 21:78-81, Loewen,S.C.&Anderson,B.A., 1990
Deteriorating Ischemic Stroke:Risk Factors and Prognosis
Neurol 40:1865-1869, Davalos,A.,et al, 1990
Pathophysiology & Clinical Assessment of Motor Symptoms in Parkinson's Disease
In Handbk of Parkinson's Disease, Marcel Dekker, Inc, New York, p997., Jankovic,J., 1987